From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
By A. Ashkenazi, W. Fairbrother, J. Leverson, A. Souers. Nature reviews. Drug discovery, 2017
819 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/33e47eb9d2a40a19a5ea2a9d58ab8337f3362e02
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Guido Kroemer
- Douglas R. Green
- L. Galluzzi
- Beth Levine
- Simone Fulda
- D. Tang
- Junying Yuan
- D. Klionsky
In Oncology
In Public Health, Environmental and Occupational Health
- Guido Kroemer
- Beth Levine
- D. Klionsky
- Douglas R. Green
- L. Galluzzi
- P. Boya
- G. Núñez
- Michael O. Hengartner
Citations in the corpus
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018, background): “Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinic”
- Mitochondrial metabolism and cancer (2017, background): “As mentioned above, this notion drove an intensive wave of research aimed at the identification of molecules that would kill transformed cells or sensitize to treatment by priming MOMP or MPT, such as the FDA-approved agent venatoclax [21].”